Addressing COVID-19 challenges: Quick wins for medical affairs leaders

Posted by Sunil John on Fri, May 08, 2020

Access COVID-19 resources

The current COVID-19 crisis has rapidly changed the face of the world and the pharmaceutical industry landscape. Virtual trials, large-scale use of telemedicine and non-personal engagements are a few such changes that the pharmaceuticals world is experiencing, and pharma companies need to adapt swiftly.


>
Read More

Innovation Is Healthcare’s New Normal

Posted by Pratap Khedkar on Fri, Aug 02, 2019

Sometimes it’s hard to keep in mind that healthcare was once considered a stodgy, conservative industry—at least by outsiders. Advances in care development and delivery happened, but the healthcare experience was generally the same as it had been decades before, as were the business models leveraged across the healthcare landscape. We’d grown, maybe not comfortable with, but accepting of the status quo.


>
Read More

Is ‘BerkshAmazMorgan’ Testing a Cure for What Ails US Healthcare?

Posted by Pratap Khedkar on Thu, Mar 29, 2018

Paul Darling co-wrote this blog post with Pratap Khedkar.

This is the second post in a two-part series on the recently announced Berkshire Hathaway/Amazon/JPMorgan Chase healthcare venture. 

The U.S. healthcare system is broken. Most healthcare stakeholders now are willing to admit that, and many are actively trying to fix it—or at least starting to talk about what it would take to do so. Many of the recent consolidations and vertical integrations are the involved parties’ attempts at solving for links in the healthcare chain that they previously had no access to, or influence over. Now three giants from corporate America are looking to wade deeper into healthcare delivery to see if they can make some fixes for their employees—and for themselves.


>
Read More

What’s ‘BerkshAmazMorgan’ Really Capable Of?

Posted by Howard Deutsch on Tue, Feb 20, 2018

Bill Coyle, Paul Darling and Pratap Khedkar co-authored this post with Howard Deutsch.

This is the first post in a two-part series on the recently announced Berkshire Hathaway/Amazon/JPMorgan Chase healthcare venture. 

Look! Out in the distance! What’s that creature that’s destroying everything in its path? Why, it’s the scariest three-headed monster this side of Cerberus! It’s… it’s… it’s BerkshAmazMorgan! Will any of us be safe from this dreaded, rampaging beast?


>
Read More

Five Steps to Address the Pain Points of Co-Pay Accumulator Programs

Posted by Howard Deutsch on Wed, Jan 31, 2018

In the cat-and-mouse co-pay card game, payers have made their next move. Pharmacy benefit managers have been promoting “co-pay accumulator” programs to plan sponsors as a way to reduce specialty drug spending. Left alone, these programs will result in confused patients who are less likely to adhere to their medications, and high costs for pharmaceutical manufacturers. Pharma companies need to respond.


>
Read More